<DOC>
	<DOCNO>NCT00227448</DOCNO>
	<brief_summary>The ultimate goal multicenter , phase II study increase blood pressure either neurologic response see target mean arterial pressure 30 % baseline achieve . IV fluid , IV phenylephrine and/or IV norepinephrine use rapidly raise mean arterial pressure control manner serial assessment neurologic function perform .</brief_summary>
	<brief_title>Induced Hypertension Acute Ischemic Stroke</brief_title>
	<detailed_description>This multicenter , pilot clinical trial . The primary outcome variable presence absence improvement NIHSS treatment induce hypertension number adverse event . The secondary outcome variable final infarct size MRI 1 month Barthel Index Modified Rankin Scale 3 month . All patient fulfil inclusion exclusion criterion willing participate receive intervention induce hypertension , include intravenous saline , phenylephrine ( neosynephrine ) levophed , possibly oral midodrine . Blood pressure increase maximum mean arterial pressure ( MAP ) 30 % baseline MAP measure emergency department . The acute phase study last 3-5 day ( responder ) patient follow 1 3 month post stroke onset . All patient undergo neurologic , cognitive , physical examination well serial MRI study diffusion perfusion-weighted imaging . Primary hypothesis measure use National Institutes Health Stroke Scale ( NIHSS ) MRI . Improvement follow induced hypertension measure compare NIHSS perform multiple time point throughout study . The ability predict diffusion-perfusion mismatch determine compare MRI # 1 MRI # 2 . NIHSS MRI also compare determine NIHSS correlate reperfusion area MRI . The secondary hypothesis improve long-term outcome measure use Barthel Index , modify Rankin Scale , MRI/Flair 1 3 month post stroke symptom onset .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<mesh_term>Midodrine</mesh_term>
	<criteria>Patients acute ischemic stroke treatment initiate within 12 hour clearly define symptom onset . ( If patient awaken deficit , time onset consider time patient last see function normally . ) Age old 18 year age . Measurable neurologic deficit isolate facial weakness , sensory loss ataxia . NIHSS must &gt; 4 point . Head CT show evidence intracranial hemorrhage mass lesion might increase risk bleed . Absence ischemic change EKG ( i.e . &gt; 1mm ST segment elevation depression least two contiguous lead , new T wave inversion two lead ) . No contraindication MRI study , include allergy gadolinium . History unstable angina , recent angina ( define chest pain ) past 3 month , recent myocardial infarction ( le 3 month ) , history ventricular arrhythmia , presence leave ventricular bundle branch block EKG . History severe symptomatic cardiac valvular disease . History congestive heart failure , dilate cardiomyopathy , hypertrophic obstructive cardiomyopathy , know ejection fraction &lt; 25 % . Systolic blood pressure great &gt; 200 mm Hg MAP &gt; 120 mm HG patient initially monitor . Serum creatinine great 2 mg/dl . History symptomatic peripheral vascular disease Raynaud 's syndrome . Suspected seizure onset stroke . Treatment IV tPA thrombolytic agent . Massive stroke ( &gt; 2/3 MCA territory ) amount midline shift due cerebral edema head CT. Pregnancy Current use MAO inhibitor , tricyclic antidepressant medication , cyclopropane halothane anesthetic agent . Coma . Allergies know contraindication use IV phenylephrine , IV norepinephrine , sodium metabisulfite , oral midodrine . Hemorrhage initial MRI CT structural lesion might raise risk intracranial bleeding . Thrombocytopenia ( plt &lt; 100 k ) , PTT &gt; 100 sec , INR &gt; 3.0 time treatment . Participation investigational trial within 30 day . Moderate severe baseline disability ( prestroke Rankin score &gt; 3 ) , severe terminal concurrent medical illness expect survival &lt; 3 month , concurrent medical psychiatric condition may limit neurologic assessment patient followup opinion investigator . Requirement anticoagulation IV heparin warfarin first 48 hour enrollment . Inability unwillingness subject legal guardian/representative give write informed consent . Toxicology screen positive cocaine . Intubated time enrollment . Mesenteric peripheral vascular thrombosis . Profound hypoxia hypercarbia define PaO2 level le 50 PaCO2 level great 60 . Norepinephrine Exclusion Criteria The patient receive Norepinephrine patient follow : lack sufficient vascular access ( central line peripheral line great 18 gauge sufficient ) , hypersensitivity norepinephrine product , severe hypertension 4.2.4 , tachycardia define HR &gt; 100 10 minute sustain , myocardial infarction , pulmonary edema , peripheral ischemia , ventricular arrhythmia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Ischemic</keyword>
	<keyword>Stroke</keyword>
</DOC>